Immune checkpoint inhibitors are a reality for the treatment of patients with NSCLC, and if approved for SCLC, would be a treatment breakthrough we have not seen for decades.
Leora Horn, MD, MSc
Advertisement
Articles by Leora Horn, MD, MSc
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer
2
FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC
3
FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer
4
Exercise Regimen Improved Outcomes Post Surgical Treatment in Breast Cancer
5